2seventy bio 
Welcome,         Profile    Billing    Logout  
  Products    Diseases    Trials    News 
13 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Abecma (idecabtagene vicleucel) / BMS, 2seventy bio
KarMMa-3, NCT03651128 / 2018-001023-38: Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

Checkmark [VIRTUAL] KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma
Checkmark The B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T Cell Therapy Idecabtagene Vicleucel (IdeCel; Bb2121) in Relapsed and Refractory Multiple Myeloma (Rrmm): Outcomes from a Phase 1 Study Support the Phase 3 Karmma-3 Study Design to Comp…
Checkmark BCMA CAR-T-Cell Therapy (ide-cel idecabtagen-vicleucel) in Relapsed and Refractory Multiple Myeloma (RRMM): Results of the Phase 1 Study Support the design of the Phase 3 study KarMMa-3 comparing ide-cel with triplicate combinations standard of care
Recruiting
3
381
Europe, Canada, Japan, US
bb2121, Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Ixazomib, Lenalidomide, Carfilzomib, Elotuzumab
Celgene
Multiple Myeloma
05/22
11/25
KarMMa-2, NCT03601078 / 2018-000264-28: An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma

Checkmark [VIRTUAL] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM): KARMMA HIGH-RISK SUBGROUP ANALYSES
Recruiting
2
181
Europe, US
bb2121
Celgene
Multiple Myeloma
08/22
02/27
NCT05032820: MM CAR-T to Upgrade Response BMT CTN 1902

Not yet recruiting
2
40
US
Lenalidomide and bb2121, ide-cel, revlimid
Marcelo Pasquini, MD, National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network, National Cancer Institute (NCI), National Marrow Donor Program, Celgene a wholly owned subsidiary of BMS
Multiple Myeloma
04/23
02/25
KarMMa, NCT03361748 / 2017-002245-29: Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Hourglass Dec 2021 - Dec 2021 : Data from KarMMa trial for r/r multiple myeloma at ASH 2021
Checkmark Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma
Checkmark Idecabtagene Vicleucel (ide-cel, bb2121), a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy: Qualitative Analyses of Post-Treatment Interviews (Months 6–24) for Patients with Relapsed and Refractory Multiple Myeloma in the Kar.…
Checkmark Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (id…
Checkmark Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study
More
Active, not recruiting
2
149
Europe, Canada, Japan, US
bb2121
Celgene
Multiple Myeloma
11/24
11/24
KarMMa-7, NCT04855136: Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma

Checkmark KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
Recruiting
1/2
415
Europe, US
BB2121, ide-cel, CC-220, BMS-986405, JSMD194, Pomalidomide, Dexamethasone, Bortezomib
Celgene
Multiple Myeloma
11/24
04/26
CRB-401, NCT02658929: Study of bb2121 in Multiple Myeloma

Checkmark Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma
Checkmark Subsequent Anti-Myeloma Therapy after Idecabtagene Vicleucel (ide-cel, bb2121) Treatment in Patients with Relapsed/Refractory Multiple Myeloma from the KarMMa Study
Checkmark Data from CRB-401 study in relapsed/refractory multiple myeloma at ASH 2020
Checkmark [VIRTUAL] Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy, in Patients with Relapsed and Refractory Multiple Myeloma: Updated Results from Phase 1 CRB-401 Study
Checkmark [VIRTUAL] MARKERS OF INITIAL AND LONG-TERM RESPONSES TO IDECABTAGENE VICLEUCEL (IDE-CEL; BB2121) IN THE CRB-401 STUDY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
More
Active, not recruiting
1
67
US
bb2121
Celgene, bluebird bio
Multiple Myeloma
07/19
12/22
KarMMa-4, NCT04196491: A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Checkmark [VIRTUAL] KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.
Checkmark [VIRTUAL] KarMMa-4: Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T-Cell Therapy, in High-Risk Newly Diagnosed Multiple Myeloma
Recruiting
1
60
US
bb2121 carfilzomib, ide-cel, Fludarabine, Cyclophosphamide, Lenalidomide
Celgene
Multiple Myeloma
01/25
01/25
NCT04771078: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Available
N/A
US
Nonconforming idecabtagene vicleucel, BB2121
Celgene
Multiple Myeloma
 
 
bb21217 / BMS, 2seventy bio
CRB-402, NCT03274219: Study of bb21217 in Multiple Myeloma

Hourglass Dec 2021 - Dec 2021 : From CRB-402 trial for multiple myeloma at ASH 2021
Checkmark Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma
Checkmark Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
Checkmark Data from trial for multiple myeloma at ASH 2020
Checkmark [VIRTUAL] Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes
More
Active, not recruiting
1
72
US
bb21217
bluebird bio
Multiple Myeloma
10/25
10/25
T-cell receptor therapy / Regeneron, 2seventy bio
NCT04614571: T Cell Receptor (TCR) Sequencing and Transcriptional Profiling in Adult Celiac Disease Patients Undergoing Gluten Challenge

Recruiting
N/A
20
US
Gluten Powder
Regeneron Pharmaceuticals
Celiac Disease
05/22
05/22
MCC1 TCR / Fred Hutchinson Cancer Research Center, 2seventy bio
ATTAC-MCC, NCT03747484: Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Recruiting
1/2
16
US
Autologous MCPyV-specific HLA-A02-restricted TCR-transduced CD4+ and CD8+ T-cells FH-MCVA2TCR, Autologous CD8+ and CD4+ T-cells transduced with TCR A2-MCC1, FH-MCVA2TCR, , FH-MCVA2TCR Autologous CD8+ and CD4+ T-cells Transduced with TCR A2-MCC1, Avelumab, 1537032-82-8, Bavencio, Immunoglobulin G1-lambda1, Anti-(Homo sapiens CD274 (Programmed Death Ligand 1, PDL1, pd-l1, B7 Homolog 1, B7H1)), Homo sapiens Monoclonal Antibody, MSB-0010718C, MSB0010718C, Pembrolizumab, Anti-(Human Programmed Cell Death 1), Keytruda, Lambrolizumab, MK-3475, SCH 900475, Radiation Therapy, Cancer Radiotherapy, ENERGY_TYPE, Irradiate, irradiated, Irradiation, NOS, Radiotherapeutics, RADIOTHERAPY, RT
Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI), bluebird bio
Other Skin
10/23
10/23
SC-DARIC33 / 2seventy bio
PLAT-08, NCT05105152: A Study Of SC-DARIC33 In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML

Recruiting
1
18
US
SC-DARIC33
Seattle Children's Hospital, 2seventy bio
Acute Myeloid Leukemia, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
02/24
01/39
bbT369 / 2seventy bio
NCT05169489: A Phase 1/2 Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL)

Not yet recruiting
1/2
50
US
bbT369
2seventy bio
Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal (Thymic) Large B Cell Lymphoma (PMBCL), High-grade B Cell Lymphoma (HGBCL), Follicular Lymphoma (FL) 3b, DLBCL Transformed From FL
12/23
08/25

Download Options